Skip to main content

Table 3 Relative expression of selected genes commonly regulated in Post- vs Pre-CPB right atrial samples from ToF and ASD patients

From: Transcriptome analysis defines myocardium gene signatures in children with ToF and ASD and reveals disease-specific molecular reprogramming in response to surgery with cardiopulmonary bypass

Function

Gene symbol

Gene description

Fold changea

ToF

ASD

Trascription regulation

ATF3

Activating transcription factor 3

35.8

13.4

EGR3

Early growth response 3

27.0

13.0

NR4A2

Nuclear receptor subfamily 4, group A, member 2

20.7

18.2

NR4A3

Nuclear receptor subfamily 4, group A, member 3

19.6

4.8

FOSB

FBJ murine osteosarcoma viral oncogene homolog B

14.9

28.8

MAFF

v-maf avian musculoaponeurotic fibrosarcoma oncogene homolog F

12.0

8.4

JUNB

Jun B proto-oncogene

10.3

9.4

EGR2

Early growth response 2

9.8

5.9

EGR1

Early growth response 1

8.8

20.5

NR4A1

Nuclear receptor subfamily 4, group A, member 1

6.5

5.3

NFKBIZ

Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, zeta

6.3

2.2

MYC

v-myc avian myelocytomatosis viral oncogene homolog

6.0

3.8

FOS

FBJ murine osteosarcoma viral oncogene homolog

5.9

13.9

JUN

Jun proto-oncogene

5.9

3.9

KLF4

Kruppel-like factor 4 (gut)

5.7

4.5

CSRNP1

Cysteine-serine-rich nuclear protein 1

5.6

4.8

IER3

Immediate early response 3

4.6

2.3

FOSL2

FOS-like antigen 2

4.5

2.8

IER2

Immediate early response

2 4.0

5.0

HES1

Hes family bHLH transcription factor 1

3.9

2.2

NFIL3

Nuclear factor, interleukin 3 regulated

3.9

2.4

KLF2

Kruppel-like factor 2

2.3

2.2

Regulation of cell growth and apoptosis

MIR21/VMP1

MicroRNA 21/vacuole membrane protein 1

11.4

5

DUSP5

Dual specificity phosphatase 5

5.4

3.1

GADD45B

Growth arrest and DNA-damage-inducible, beta

5.2

2.6

CDKN1A

Cyclin-dependent kinase inhibitor 1A (p21, Cip1)

5.1

2.7

MIR22/MIR22HG

MicroRNA 22/MIR22 host gene

4.5

2.8

MCL1

Myeloid cell leukemia 1

4.4

2.5

MIR23A/MIR24-2

MicroRNA 23a/24-2

4.3

3.3

BTG2

BTG family, member 2

4.0

2.6

DUSP6

Dual specificity phosphatase 6

3.7

3.2

CCNL1

Cyclin L1

3.7

2

PPP1R15A/GADD34

Protein phosphatase 1, regulatory subunit 15A/growth arrest and DNA-damage-inducible

3.3

2.1

DUSP1

Dual specificity phosphatase 1

2.2

2.1

Inflammatory response

SOCS3

Suppressor of cytokine signaling 3

23.0

24.6

PTGS2

Prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase)

12.2

6.9

CCL2

Chemokine (C–C motif) ligand 2

10.4

6.2

CXCL2

Chemokine (C–X–C motif) ligand 2

9.3

11.7

RGS1

Regulator of G-protein signaling 1

4.0

4.8

RGS2

Regulator of G-protein signaling 2

3.6

2.0

C3

Complement component 3

0.4

0.3

ITLN1

Intelectin 1 (galactofuranose binding)

0.05

0.1

Cell adhesion and matrix organization

ADAMTS1

ADAM metallopeptidase with thrombospondin type 1 motif, 1

6.5

3.8

CYR61 (CCN1)

Cysteine-rich, angiogenic inducer, 61

5.5

5.2

THBD

Thrombomodulin

4.6

2.4

EFEMP1

EGF containing fibulin-like extracellular matrix protein 1

0.4

0.4

COL3A1

Collagen, type III, alpha 1

0.2

0.2

Antioxidant activity

MT1M

Metallothionein 1M

14.3

5.9

NCOA7

Nuclear receptor coactivator 7

4.7

2.2

MT2A

Metallothionein 2A

3.1

2.0

  1. Comparative analysis of gene expression in Pre-CPB and Post-CPB ToF and ASD samples was conducted as described in “Methods” section. A function, a gene symbol, a brief gene description, and fold change values are specified for each gene
  2. Genes for each functional category are ordered according to decreasing fold changes of ToF genes
  3. aFold change was calculated as the ratio between the mean expression value of Post-CPB and Pre-CPB samples for each gene. Fold change ≥ 2 or ≤ 0.5 are considered significant